Bone-biomarkers of Spinal Cord Injury Patients

Changes of Bone-biomarker According to the Severity of Spinal Cord Injury.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04403256

Enrollment

Registered

2020-05-27

Start date

2020-02-05

Completion date

2021-08-30

Last updated

2021-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Resorption, Osteoporosis, Spinal Cord Injuries

Keywords

Sclerostin, osteoporosis, Spinal cord injury, Unloading

Brief summary

Patients with spinal cord injury have a high prevalence of osteoporosis due to chronic skeletal unloading. Recently, various treatment drugs for osteoporosis have been developed. In particular, romosozumab, a sclerostin inhibitor, has been reported to have a high therapeutic effect as an inhibitor of bone resorption while promoting bone formation. However, there are a few research concerning sclerostin of spinal cord injuries patients. Therefore we want to analyze the change of sclerostin as well as factors indicating bone formation and absorption marker in spinal cord injury patient.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* spinal cord injury patients * Functional ambulatory category index of 3 or less

Exclusion criteria

* history of using bone absorption medication within the effective period

Design outcomes

Primary

Measure	Time frame	Description
Serum sclerostin level	1 year	Serum sclerostin level in spinal cord injury patients

Countries

South Korea

Outcome results